Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05166746
Other study ID # AVM_Lacto_2015/582
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 7, 2017
Est. completion date October 1, 2023

Study information

Verified date July 2023
Source Regionshospitalet Viborg, Skive
Contact Thor Haahr, MD
Phone +4527885402
Email thohaa@rm.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study question: Does antibiotic alone or in combination with live biotherapeutic treatment of an abnormal vaginal microbiota improve the reproductive outcomes of IVF couples? Study hypothesis: The investigator hypothesize that treatment of the reproductive tract pathogens and restoration of vaginal Lactobacillus will improve the reproductive outcomes of IVF patients. What is known already? Ultra-deep sequencing methods enable the refinement of reproductive tract microbiology in infertile patients. A recent meta-analysis reported that 19% of infertile patients had abnormal vaginal microbiota Moreover, someone have detected the presence of a Gardnerella (G.) vaginalis dominated endometrial biofilm in 50% of non-infertile patients with abnormal vaginal microbiota undergoing curettage; thus the treatment of such an endometrial biofilm might play an important role for the endometrial receptivity and subsequently the clinical pregnancy rate. Pilot study: In a recent pilot study it was observed that an abnormal vaginal microbiota negatively affects the clinical pregnancy rate in IVF patients. In this study the prevalence of abnormal vaginal microbiota was 28% (36/130) and only 9% of patients with qPCR defined abnormal vaginal microbiota obtained a clinical pregnancy (p=0.004). This association remained significant in an adjusted analysis. Furthermore, the invetigators have preliminary results demonstrating that vaginal bacteria such as G. vaginalis can be found in the endometrium of IVF patients, which is also supported by recent publications What is the novelty of this study? To the investigators knowledge, no previous treatment study of abnormal reproductive tract microbiota has been performed in IVF patients; this relatively small intervention holds the potential to increase the baby-take-home rate after IVF treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 333
Est. completion date October 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria: - Abnormal vaginal microbiota. - The screening swab should be repeated if more than 3 months old. - HIV, Hepatitis B or C positivity. - First, second or third IVF stimulation cycle or embryo transfer therefrom. - BMI<35 - Written informed consent. Exclusion Criteria: - Known or suspected hypersensitivity to clindamycin. - HPV CIN 2 or higher. - Former or current inflammatory bowel disease - Severe concomitant disease, including diabetes. - MAX 2 embryos may be transferred - Artificial heart valve - Intrauterine malformations with operation indication as determined by treating physician (Polyps, Septum, fibroma)

Study Design


Intervention

Drug:
Clindamycin
Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
Other:
Placebo
The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium. The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate

Locations

Country Name City State
Denmark Copenhagen University Hospital, Rigshospitalet Copenhagen
Denmark Stork Fertility Clinic VivaNeo Copenhagen
Denmark Hvidovre Hospital, The Fertility Clinic Hvidovre
Denmark Fertility Clinic Skive, Skive Regional Hospital Skive

Sponsors (1)

Lead Sponsor Collaborator
Peter Humaidan

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of clinical pregnancy per embryo transfer Ultrasound scan detection of intrauterine fetal heartbeat in gestational week 7-9 7-9 weeks
Secondary Cure of abnormal vaginal microbiota A vaginal swab and qPCR-validated diagnostics for abnormal vaginal microbiota 1-2 months
Secondary Live birth rate The birth of a live born child after 25 gestational weeks. 25-42 weeks depending on pregnancy.
Secondary Biochemical pregnancy positive hCG blood test 14 days gestation
Secondary Implantation rate The number of embryos implanting pregnancy scan at 7-9 weeks
Secondary early miscarriage The loss of an hCG positive pregnancy 14 days - 12 weeks gestation
Secondary Number of late miscarriage The of pregnancy in late pregnancy 12 weeks gestation - to labour (i.e. not including still birth)
Secondary Number of preterm birth birth of a liveborn prior to 37 gestational weeks
Secondary Birth weight weight at birth 25-42 weeks gestation depending on pregnancy
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer